Advanced in Bronchogenic Cyst

Dr. Daniel F. Dilling

Intensive Care Medicine | Pulmonary Medicine
Loyola University Medical Center
2160 S 1st Ave, 
Maywood, IL 
Accepting New Patients
Advanced in Bronchogenic Cyst
Loyola University Medical Center
2160 S 1st Ave, 
Maywood, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Dilling is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Maywood, Illinois. Dr. Dilling and is rated as an Advanced provider by MediFind in the treatment of Bronchogenic Cyst. His top areas of expertise are Lymphangioleiomyomatosis, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Gastrostomy. Dr. Dilling is currently accepting new patients.

His clinical research consists of co-authoring 50 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Internal Medicine in IL
Hospital Affiliations
Loyola University Medical Center
Riverside Medical Center
Northwestern Medicine Mchenry
Saint Francis Medical Center
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

LOYOLA UNIVERSITY MEDICAL CENTER
2160 S 1st Ave, Maywood, IL 60153

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Suspended
Publish Date: May 30, 2025
Intervention Type: Drug
Study Drug: ORIN1001
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Enrollment Status: Terminated
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

50 Total Publications

CD26/DPP-IV inhibitors and associations with chronic lung allograft dysfunction in a multicenter cohort.
CD26/DPP-IV inhibitors and associations with chronic lung allograft dysfunction in a multicenter cohort.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: March 26, 2025
Similar Doctors
Distinguished in Bronchogenic Cyst
Dr. Alan D. Betensley
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Bronchogenic Cyst
Dr. Alan D. Betensley
Pulmonary Medicine | Intensive Care Medicine

Northwestern Medical Faculty Foundation

676 N Saint Clair St, 
Chicago, IL 
 (11.2 mi)
Languages Spoken:
English
See accepted insurances

Alan Betensley is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chicago, Illinois. Dr. Betensley and is rated as a Distinguished provider by MediFind in the treatment of Bronchogenic Cyst. His top areas of expertise are Bronchogenic Cyst, Lung Metastases, Pulmonary Fibrosis, Lung Transplant, and Thrombectomy.

Neeraj R. Desai
Advanced in Bronchogenic Cyst
Dr. Neeraj R. Desai
Pulmonary Medicine | Intensive Care Medicine
Advanced in Bronchogenic Cyst
Dr. Neeraj R. Desai
Pulmonary Medicine | Intensive Care Medicine

Endeavor Health Medical Group

800 W Central Rd, 
Arlington Heights, IL 
 (16.4 mi)
847-618-1000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Desai is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Arlington Heights, Illinois. Dr. Desai and is rated as a Distinguished provider by MediFind in the treatment of Bronchogenic Cyst. His top areas of expertise are Pleural Effusion, Lung Nodules, Lung Cancer, Endoscopy, and Gastrostomy. Dr. Desai is currently accepting new patients.

Distinguished in Bronchogenic Cyst
Dr. Ahmad K. Agha
Pulmonary Medicine
Distinguished in Bronchogenic Cyst
Dr. Ahmad K. Agha
Pulmonary Medicine

Agha Medical Inc

1367 N Division St, 
Morris, IL 
 (45.4 mi)
815-941-2007
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ahmad Agha is a Pulmonary Medicine provider in Morris, Illinois. Dr. Agha and is rated as a Distinguished provider by MediFind in the treatment of Bronchogenic Cyst. His top areas of expertise are Lung Metastases, Pneumonia, Lung Nodules, Advanced Bronchoscopy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dilling's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile